We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PhRMA: RISK MANAGEMENT GUIDANCES MAY HAVE CONSEQUENCES
PhRMA: RISK MANAGEMENT GUIDANCES MAY HAVE CONSEQUENCES
July 12, 2004
While the FDA’s promulgation of three draft guidance documents on risk assessment and minimization will go a long way to establishing a framework for industry and the agency, some components of the guidances may actually delay the availability of new and beneficial drugs, according to PhRMA.